RxDoctor Payments Data

Alexandra Filippakis, DO

Neurology · Haverhill, MANPI 1508270596

Payments from drug & device makers

$94,235in general payments, 2019–2025

Across 128 payments — averaging $736.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$52K
  • AbbVie$32K
  • E.r. Squibb & Sons, L.L.C.$8K
  • Bristol Myers Squibb$1K
  • Biogen$150
  • TG Therapeutics, Inc.$134
  • plus $383 from 7 others

What the payments were for

  • Consulting fees$7,8508%
  • Speaking & faculty fees$81,50086%
  • Travel & lodging$3,1583%
  • Food & beverage$1,6992%
  • Education$290%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$94,235 in reported general payments places this provider in the 80th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$60,009
Medicare patients
237
Services billed
2,503

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab30$308,354
VumerityDiroximel Fumarate12$96,856
QuliptaAtogepant55$58,680
Aimovig AutoinjectorErenumab-Aooe60$49,275
UbrelvyUbrogepant43$45,926
Emgality PenGalcanezumab-Gnlm22$15,084
Emgality SyringeGalcanezumab-Gnlm15$11,398
Dalfampridine ErDalfampridine30$9,360
EliquisApixaban12$6,760
Donepezil Hcl102$3,829
Gabapentin103$3,620
Lacosamide13$3,212
Teriflunomide36$2,401
Baclofen96$2,358
Dimethyl Fumarate12$2,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$32,305$104,60698 claims
BiogenVumerity$150$96,85612 claims
PfizerEliquis$44$6,76012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 761 neurology providers in Massachusetts.

Other neurology in Haverhill

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →